- Cytomegalovirus (CMV) retinitis, a vision-threatening viral eye infection, remains a significant concern among immunocompromised individuals, particularly those with advanced HIV/AIDS or undergoing immunosuppressive therapies such as organ transplantation or chemotherapy. Rising awareness, improved diagnostics, and the availability of antiviral therapies are accelerating market growth globally
- The growing prevalence of CMV infections, especially in developing nations, coupled with the increasing use of immunosuppressive drugs, is contributing to the rising incidence of CMV Retinitis. These trends are propelling the demand for early detection tools and effective antiviral treatments
- North America dominated the Cytomegalovirus retinitis market with the largest revenue share of 40.05% in 2024, attributed to the presence of well-established healthcare infrastructure, higher diagnosis rates, and access to advanced antiviral therapies such as ganciclovir and valganciclovir. The U.S. continues to lead the region due to its supportive reimbursement policies and strong presence of key pharmaceutical players
- Asia-Pacific is expected to be the fastest-growing region in the Cytomegalovirus retinitis market, with a projected CAGR of 9.1% from 2025 to 2032, driven by rising HIV prevalence, increasing healthcare awareness, rapid urbanization, and improving access to antiviral medications. Countries such as India, China, and Thailand are contributing significantly to the regional market expansion
- The uveitis segment dominated the Cytomegalovirus retinitis market with a market revenue share of 37.6% in 2024, driven by its direct correlation with CMV infection in immunocompromised individuals. Uveitis, particularly posterior and panuveitis, is commonly observed in CMV retinitis cases, especially in patients with advanced HIV/AIDS
